SOST and sclerosteosis: This approach was further supported by the gene-dose effect suggested by findings in heterozygous carriers of sclerosteosis who demonstrated decreased serum sclerostin levels associated with increased levels of P1NP and high normal or increased BMD without any clinical symptoms, signs, or complications of sclerosteosis [53, 54].